Your browser is no longer supported. Please, upgrade your browser.
Acasti Pharma Inc.
Index- P/E- EPS (ttm)-0.01 Insider Own- Shs Outstand106.26M Perf Week-2.00%
Market Cap52.07M Forward P/E2.23 EPS next Y0.22 Insider Trans- Shs Float50.57M Perf Month-7.55%
Income- PEG- EPS next Q- Inst Own- Short Float0.33% Perf Quarter-12.50%
Sales0.23M P/S223.59 EPS this Y57.10% Inst Trans- Short Ratio1.17 Perf Half Y-51.96%
Book/sh0.26 P/B1.88 EPS next Y466.70% ROA- Target Price6.25 Perf Year-58.47%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.35 - 1.22 Perf YTD-2.00%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-59.84% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low40.00% ATR0.04
Employees- Current Ratio- Sales Q/Q1.70% Oper. Margin- RSI (14)46.84 Volatility5.52% 8.84%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.12 Prev Close0.48
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume140.93K Price0.49
Recom2.00 SMA20-2.97% SMA501.16% SMA200-29.47% Volume17,241 Change2.08%
Mar-25-15 07:30AM  Acasti Granted Composition & Use Patent in China GlobeNewswire
Mar-23-15 07:05PM  USPTO Issues Positive Decision That Triggers Royalty Payments to Neptune GlobeNewswire
Mar-02-15 07:30AM  Acasti Receives Full Data for Phase II TRIFECTA Trial GlobeNewswire -5.45%
Feb-26-15 02:24PM  Acasti Pharma Gains Ahead Of Expected Phase II Results +5.66%
Feb-05-15 07:28AM  Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune GlobeNewswire
Jan-13-15 05:05PM  Acasti Announces Third Quarter Results GlobeNewswire -7.14%
Nov-11-14 08:00AM  Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements GlobeNewswire
Oct-20-14 07:59AM  Acasti Announces Grant of Stock Options GlobeNewswire
Oct-15-14 05:03AM  Acasti posts 2Q loss
Oct-14-14 07:53AM  Acasti Announces Second Quarter Results GlobeNewswire -22.22%
07:52AM  Neptune Announces Second Quarter Results GlobeNewswire
Sep-30-14 08:00AM  Acasti Announces Positive Top-Line Pharmacokinetic Results GlobeNewswire
Sep-29-14 08:00AM  Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C GlobeNewswire -20.41%
Aug-13-14 01:10PM  Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View
Jul-24-14 07:45AM  Acasti Pharma (ACST) Jumps: Stock Moves 7.3% Higher
07:00AM  Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston GlobeNewswire
Jul-15-14 05:48PM  Acasti Announces First Quarter Results GlobeNewswire
Jul-10-14 06:48AM  Acasti Pharma Inc. (ACST) Jumps: Stock Rises 7.6%
Jul-09-14 11:48AM  Why Acasti Pharmaceuticals (ACST) Stock Is Up Today at TheStreet +8.00%
08:00AM  Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials GlobeNewswire
Jun-26-14 04:13PM  Acasti Grants of Stock Options to Newly Appointed Board Members Marketwired
Jun-23-14 07:07AM  Acasti Pharma Inc (ACST) Jumps: Stock Rises 7.2% in Session Zacks -5.04%
Jun-20-14 09:45AM  Acasti Reports Results of Annual and Special Meeting GlobeNewswire +7.21%
Jun-17-14 01:04PM  ACASTI PHARMA INC. Financials EDGAR Online Financials
Jun-16-14 07:00AM  Acasti Announces Resignation of Chief Financial Officer GlobeNewswire
03:42AM  Acasti Pharma (ACST) Soars: Stock Adds 10.0% in Session Zacks
May-30-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer Marketwired
May-23-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEO GlobeNewswire
May-21-14 05:29PM  Acasti Announces Fourth Quarter and Fiscal Year Results GlobeNewswire -6.25%
May-01-14 08:29AM  Acasti to Present at Two Scientific Forums GlobeNewswire
Apr-28-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer GlobeNewswire +6.19%
Apr-27-14 08:32PM  Neptune and Enzymotec Conclude Final Patent Infringement Settlement and License Agreement GlobeNewswire
Apr-15-14 08:57AM  Activist Trying To Unlock A Potential 65% Upside In Neptune at Seeking Alpha -8.11%
Apr-01-14 02:24PM  Neptune & Acasti Give Update on Patent Litigations With Enzymotec GlobeNewswire
08:27AM  Acasti Pharma: An Undervalued Biotech With A Potential Best-In-Class Omega-3 Drug at Seeking Alpha
Mar-18-14 09:41PM  4 Stocks Under $10 to Trade for Breakouts at TheStreet
Feb-21-14 10:00AM  Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High at Seeking Alpha
Feb-14-14 09:52AM  Neptune and Acasti Provide Update on Patent Litigations With Enzymotec GlobeNewswire
09:40AM  Acasti and Neptune Provide Update on Patent Litigations with Enzymotec GlobeNewswire
Feb-07-14 08:00AM  Acasti Announces Closing of CAD$2.15 Million Private Placement GlobeNewswire
Feb-06-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet
Jan-21-14 11:46AM  Neptune Erecting A Moat In Omega-3; Shares Undervalued at Seeking Alpha
Jan-14-14 07:30AM  Acasti Announces Third Quarter Results GlobeNewswire
Jan-11-14 08:34AM  While Amarin Continues To Go Rancid, Neptune Will Soar at Seeking Alpha
Jan-09-14 07:30AM  FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial GlobeNewswire
Dec-19-13 07:30AM  Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors GlobeNewswire
Dec-17-13 08:45AM  Neptune, Acasti reach patent settlement and license pact with Aker BioMarine
08:30AM  Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement GlobeNewswire
Dec-16-13 06:07PM  Nasdaq stocks posting largest volume increases AP -8.70%
Dec-10-13 05:01PM  Acasti Pharma: 7 Different Insiders Have Purchased Shares This Month at Seeking Alpha
Dec-03-13 10:14AM  Acasti Announces Closing of US$23 Million Underwritten Offering of Units GlobeNewswire
Nov-27-13 09:22AM  InPlay: Acasti Pharma prices public offering of 16 mln units of Acasti at $1.25 per Unit, each Unit consisting of one Class A share and one Common Share purchase warrant of Acasti -13.67%
09:19AM  Acasti Announces Pricing of US$20 Million Offering of Units GlobeNewswire
Nov-26-13 04:01PM  Acasti Announces Proposed Offering of Units GlobeNewswire
Nov-11-13 08:30AM  Acasti Completes PK IND Submission GlobeNewswire +5.24%
Nov-05-13 08:30AM  Reed V. Tuckson, M.D. Joins Acasti's Board of Directors GlobeNewswire
Oct-29-13 08:30AM  Acasti Strengthens Its IP Portfolio GlobeNewswire
Oct-15-13 08:00AM  Acasti Announces Second Quarter Results GlobeNewswire
Oct-02-13 09:45AM  Patent Infringement Settlements Reached GlobeNewswire +5.96%
Aug-13-13 07:46PM  4 Healthcare Stock Stories For Tuesday Investment Wellness at Wall St. Cheat Sheet
08:49AM  Acasti announces positive phase 2 open label clinical trial result at
08:40AM  Acasti Announces Positive Phase II Open Label Clinical Trial Results GlobeNewswire
Jul-31-13 08:00AM  Acasti Signs Manufacturing Agreement GlobeNewswire
Jul-15-13 08:00AM  Acasti Announces First Quarter Results GlobeNewswire
Jul-12-13 10:43PM  Neptune Announces Issuance of Shares Under Previously Announced Royalty Prepayment Agreement That Increases Its Equity Participation in Acasti Pharma Inc. GlobeNewswire
Jul-09-13 02:28PM  Acasti Pharma: Increasing Investor Interest And Volatility Likely Cometh at Seeking Alpha
05:10AM  Small-Cap Biotechs With Blockbuster Potential: Hugh Cleland at Seeking Alpha
Jul-03-13 05:38PM  Five 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
05:38PM  5 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.